

115 responded to recruitment advertisement

1<sup>st</sup> and 2<sup>nd</sup> phase  
Screening for eligibility

35 excluded  
21 met exclusion criteria  
14 had higher CVs in SIgA

80 eligible subjects

Placebo group  
(N = 40)

b240 group  
(N = 40)

Exclusion

week 0 (n = 10)  
took forbidden drug (N = 3),  
changed affecting drug (N = 1), or  
poor compliance (N = 1)  
week 2 (n = 10)  
week 4 (n = 14)  
took forbidden drug (N = 1), or  
affecting drug (N = 1)  
week 6 (n = 14)  
took forbidden drug (N = 1)  
week 8 (n = 14)  
week 10 (n = 16)  
took forbidden drug (N = 1)  
week 12 (n = 20)  
took forbidden drug (N = 1), or  
affecting drug (N = 1)

Saliva collection

week 0 (n = 79)  
no saliva (n = 1)  
week 2 (n = 78)  
absence (N = 1)  
week 4 (n = 80)  
week 6 (n = 78)  
absence (N = 1)  
week 8 (n = 74)  
absence (N = 3)  
week 10 (n = 76)  
absence (N = 2)  
week 12 (n = 80)

Analysis

week 0 (n = 70)  
week 2 (n = 68)  
week 4 (n = 66)  
week 6 (n = 64)  
week 8 (n = 62)  
week 10 (n = 60)  
week 12 (n = 60)

Saliva collection

week 0 (n = 80)  
week 2 (n = 79)  
handling mistake (n = 1)  
week 4 (n = 80)  
week 6 (n = 80)  
week 8 (n = 72)  
absence (N = 4)  
week 10 (n = 80)  
week 12 (n = 80)

Analysis

week 0 (n = 76)  
week 2 (n = 75)  
week 4 (n = 70)  
week 6 (n = 72)  
week 8 (n = 62)  
week 10 (n = 70)  
week 12 (n = 66)

Exclusion

week 0 (n = 4)  
took forbidden drug (N = 1), or  
changed affecting drug (N = 1)  
week 2 (n = 4)  
took affecting drug (N = 1)  
week 4 (n = 10)  
took forbidden drug (N = 3), or  
affecting drug (N = 1)  
week 6 (n = 8)  
week 8 (n = 10)  
took affecting drug (N = 1)  
week 10 (n = 10)  
took forbidden drug (N = 1)  
week 12 (n = 14)  
poor compliance (N = 1), or took  
affecting drug (N = 1)